Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 8/20 | 0.43 |
| ▸ | PPARA | Q07869 | 6/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24309913 | 0.86 | CA4 (0.43) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL507063 | 0.86 | CA4 (0.43) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| Hydrochloric Acid SCHEMBL28234445 | 0.84 | POLB (0.42) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL9487460 | 0.83 | LTA4H (0.52) | MAOACA1CA2CA9PPARG | |
| SCHEMBL4178299 | 0.82 | GAA (0.62) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL13741203 | 0.78 | CYP1A2 (0.58) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL9228207 | 0.78 | CYP1A2 (0.63) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL8638375 | 0.78 | LTA4H (0.57) | CYP1A2CYP2C9CYP2C19MAOAPPARG | |
| Acetic Acid SCHEMBL359202 | 0.77 | MTNR1A (0.51) | CYP1A2GAACYP2C9PKMCYP2C19 | |
| SCHEMBL9870750 | 0.77 | CYP1A2 (0.56) | CYP1A2GAACYP2C9PKMCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250345785-A1 | ANIONIC EXCHANGE-HYDROPHOBIC MIXED MODE CHROMATOGRAPHY RESINS | BIO RAD LABORATORIES INC (US) | 2025-11-13 | — | — | US | claimed |
| US-11896969-B2 | Anionic exchange-hydrophobic mixed mode chromatography resins | BIO-RAD LABORATORIES, INC. (US) | 2024-02-13 | — | — | US | claimed |
| US-20030212067-A1 | Matrix metalloprotease inhibitors | CASTELHANO ARLINDO LUCAS (US) | 2003-11-13 | — | — | US | claimed |
| US-6037472-A | FOR TREATING DISEASE-STATES CHARACTERIZED BY EXCESSIVE ACTIVITY OF MATRIX METALLOPROTEASES SUCH AS RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTAL DISEASE, ABERRANT ANGIOGENESIS, TUMOR INVASION AND METASTASIS | SYNTEX (U.S.A.) INC. (US) | 2000-03-14 | — | — | US | claimed |
| EP-0793643-A1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1997-09-10 | — | — | EP | claimed |
| WO-1996016027-A1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1996-05-30 | — | — | WO | claimed |
| US-20250345785-A1 | ANIONIC EXCHANGE-HYDROPHOBIC MIXED MODE CHROMATOGRAPHY RESINS | BIO RAD LABORATORIES INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12364978-B2 | Anionic exchange-hydrophobic mixed mode chromatography resins | BIO-RAD LABORATORIES, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| US-20240261775-A1 | ANIONIC EXCHANGE-HYDROPHOBIC MIXED MODE CHROMATOGRAPHY RESINS | BIO-RAD LABORATORIES, INC. | 2024-08-08 | — | — | US | disclosed |
| US-11896969-B2 | Anionic exchange-hydrophobic mixed mode chromatography resins | BIO-RAD LABORATORIES, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-20210069692-A1 | ANIONIC EXCHANGE-HYDROPHOBIC MIXED MODE CHROMATOGRAPHY RESINS | BIO-RAD LABORATORIES, INC. | 2021-03-11 | — | — | US | disclosed |
| US-20030212067-A1 | Matrix metalloprotease inhibitors | CASTELHANO ARLINDO LUCAS (US) | 2003-11-13 | — | — | US | disclosed |
| US-6579890-B1 | Matrix metalloprotease inhibitors | SYNTEX (U.S.A.) INC. | 2003-06-17 | — | — | US | disclosed |
| US-6037472-A | FOR TREATING DISEASE-STATES CHARACTERIZED BY EXCESSIVE ACTIVITY OF MATRIX METALLOPROTEASES SUCH AS RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTAL DISEASE, ABERRANT ANGIOGENESIS, TUMOR INVASION AND METASTASIS | SYNTEX (U.S.A.) INC. (US) | 2000-03-14 | — | — | US | disclosed |
| EP-0793643-A1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1997-09-10 | — | — | EP | disclosed |
| WO-1996016027-A1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1996-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250345785-A1 | ANIONIC EXCHANGE-HYDROPHOBIC MIXED MODE CHROMATOGRAPHY RESINS | ABCG2, SLC7A1, MSR1 | CYP1A2 4836/4885GAA 1654/4885CYP2C9 4316/4885 |
| US-12364978-B2 | Anionic exchange-hydrophobic mixed mode chromatography resins | ABCG2, SLC7A1, MSR1 | CYP1A2 4836/4885GAA 1654/4885CYP2C9 4316/4885 |
| US-20240261775-A1 | ANIONIC EXCHANGE-HYDROPHOBIC MIXED MODE CHROMATOGRAPHY RESINS | ABCG2, SLC7A1, MSR1 | CYP1A2 4836/4885GAA 1654/4885CYP2C9 4316/4885 |
| US-20210069692-A1 | ANIONIC EXCHANGE-HYDROPHOBIC MIXED MODE CHROMATOGRAPHY RESINS | ABCG2, SLC7A1, MSR1 | CYP1A2 4836/4885GAA 1654/4885CYP2C9 4316/4885 |
| US-11896969-B2 | Anionic exchange-hydrophobic mixed mode chromatography resins | ABCG2, SLC7A1, MSR1 | CYP1A2 4836/4885GAA 1654/4885CYP2C9 4316/4885 |
| US-20030212067-A1 | Matrix metalloprotease inhibitors | MMP7, MMP1, MMP3 | CYP1A2 593/4885GAA 226/4885CYP2C9 1112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.